21 October 2002
Potential of CT-scan based tumor volume as a response indicator in chemotherapy of advanced epithelial ovarian cancer.
Pratik Kumar, Madan Mohan Rehani, Lalit Kumar, Raju Sharma, Neerja Bhatla, Rajvir Singh, K. Ramaiyer SundaramMed Sci Monit 2002; 8(10): CR667-674 :: ID: 4872
Abstract
BACKGROUND: Response prediction in patients undergoing chemotherapy for ovarian cancer is an important issue, since the cure rate is only about 15-20%. We attempted to develop a semi-empirical model to predict response in individual cases after the first cycle of chemotherapy. MATERIAL/METHODS: This prospective study included 51 cases of advanced ovarian cancer. A method was standardized to estimate ovarian tumor volume accurately from CT scan films. This permits the inclusion of patients who have undergone CT scan elsewhere. Patients underwent 4-6 cycles of chemotherapy and tumor volume was estimated after each cycle. This yielded a tumor regression curve for each patient. RESULTS: Percent reduction in tumor volume after the first chemo-cycle was a significant prognostic factor in multivariate analysis. Depending upon the rate of regression patients could be classified into Fast Regressing FR (n=29) and Moderately Regressing MR (n=16), whereas 6 patients showed Progressive Disease (PD) despite ongoing chemotherapy. The median survivals for the FR, MR and PD groups were 29.3, 18.9 and 8.5 months respectively. We found that 'percent reduction in volume after first chemo-cycle' could categorize a patient as FR/MR/PD correctly in 94.1% of cases. This parameter could also detect 5 out of 6 inherently resistant PD cases, who would otherwise undergo further chemotherapy, since early detection of resistance by clinical monitoring is quite difficult. CONCLUSIONS: An individual patient at risk for shorter survival and with inherent drug resistance can be identified after the first cycle of chemotherapy.
Keywords: Ovarian Neoplasms - drug therapy
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952